RnRMarketResearch.com adds “Polycystic Ovarian Syndrome – Pipeline Review, H2 2014” report to its research database. This report provides an overview of the Polycystic Ovarian Syndrome’s therapeutic pipeline.
Dallas, TX -- (SBWIRE) -- 10/15/2014 -- This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects.
Polycystic ovary syndrome (PCOS), also called hyperandrogenic anovulation (HA), or Stein-Leventhal syndrome, is one of the most common endocrine disorders among females. PCOS has a diverse range of causes that are not entirely understood, but there is evidence that it is largely a genetic disease. Others say it is generally a metabolic dysfunction, since it is reversible. Even though considered as a gynecological problem, PCOS is comprised of 28 clinical symptoms.
Even though the name suggest that the ovaries are the cornerstone of disease pathology, cysts are the 'result' , not the cause of the disease. Symptoms of PCOS will persist even if both ovaries are removed, the disease can appear even if cysts are absent. Since it's first description by Stein and Leventhal in 1935, the criteria of diagnosis, symptoms, and causative factors are subject to debate. Gynecologists often see it as a gynaecological problem, with ovary as the primary organ affected. However, recent insights shows a multisystem disorder, with the primary problems lies in hormonal regulation in hypothalamus, with involvement of many organs. The name PCOD is used when there is an ultrasonographic evidence. The term PCOS is used since there is a wide spectrum of symptoms possible, and cysts in the ovaries are seen only in 15% of people. Treatments like wedge resection or laparoscopic drilling of ovaries are still performed around the world, based on this false 'ovary- focused' belief.
Complete Report Available
PCOS produces symptoms in approximately 5% to 10% of women of reproductive age (approximately 12 to 45 years old). It is thought to be one of the leading causes of female subfertility and the most frequent endocrine problem in women of reproductive age. Finding that the ovaries appear polycystic on ultrasound is common, but it is not an absolute requirement in all definitions of the disorder.
The most common immediate symptoms are anovulation, excess androgenic hormones, and insulin resistance. Anovulation results in irregular menstruation, amenorrhea, and ovulation-related infertility. Hormone imbalance generally causes acne and hirsutism. Insulin resistance is associated with obesity, type 2 diabetes, and high cholesterol levels. The symptoms and severity of the syndrome vary greatly among affected women.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Order a Purchase copy
-The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products
Reasons to buy:
-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse more reports on Women's Health therapeutics Market